Amendments to the Claims:

1. and 2. (Cancelled)

3. (Currently amended) A multi-valent [[The]] immunogenic composition for conferring protection in a host against disease caused by infection by respiratory syncytial virus (RSV) and by influenza virus, which comprises:

(a) an immunoeffective amount of a mixture of purified fusion (F), attachment (G) and matrix (M) protein of RSV,

(b) an immunoeffective amount of non-virulent influenza virus preparation, and

(c) an adjuvant,

said immunogenic composition being formulated as a vaccine for *in vivo* administration to the host wherein the individual components (a) and (b) of the composition are formulated such that the immunogenicity of the individual components (a) and (b) is not impaired, ~~of claim 2~~

wherein said adjuvant is poly-di(carboxylatophenoxy)-phosphazene (PCPP) and imparts an enhanced immune response to RSV when compared to the mixture (a) formulated with the adjuvant in the absence of the non-virulent virus preparation, wherein said non-virulent influenza virus preparation is Fluzone®~~, formulated with the adjuvant in the absence of the non-virulent influenza virus preparation~~.

4. (Cancelled).

5. (Currently amended) The immunogenic composition of ~~claim 1~~ claim 3 wherein said mixture (a) is present in an amount of about 10 to about 200 µg and (b) is present in an amount of about 1 to about 100 µg, in a single dose.

6. (Currently amended) The immunogenic composition of ~~claim 1~~ claim 3 wherein said fusion (F) protein comprises multimeric fusion (F) proteins.

7. (Original) The immunogenic composition of claim 6 wherein, when analyzed under non-reducing conditions, said multimeric fusion (F) protein includes heterodimers of molecular weight approximately 70 kDa and dimeric and trimeric forms.

8. (Currently amended) The immunogenic composition of ~~claim 1~~ claim 3 wherein, when analyzed under non-reducing conditions, said attachment (G) protein comprises G protein of molecular weight approximately 95 kDa and G protein of molecular weight approximately 55 kDa and oligomeric G protein.

9. (Currently amended) The immunogenic composition of ~~claim 1~~ claim 3 wherein, when analyzed by SDS-PAGE under non-reducing conditions, said matrix (M) protein comprises M protein of molecular weight approximately 28 to 34 kDa.

10. (Currently amended) The immunogenic composition of ~~claim 1~~ claim 3 wherein, when analyzed by reduced SDS-PAGE analysis, said fusion (F) protein comprises an F_1 subunit of molecular weight approximately 48 kDa and an F_2 subunit of molecular weight approximately 23 kDa, said attachment (G) protein comprises a G protein of molecular weight approximately 95 kDa and a G protein of molecular weight approximately 55 kDa, and said matrix (M) protein comprises an M protein of approximately 31 kDa.

11. (Currently amended) The immunogenic composition of ~~claim 1~~ claim 3 wherein said F, G and M proteins are present in mixture (a) in the relative proportions of:

F from about 35 to about 70 wt%
G from about 5 to about 30 wt%
M from about 10 to about 50 wt%

12. (Original) The immunogenic composition of claim 11 wherein, when analyzed by SDS-PAGE under reducing conditions and silver stained, the ratio of F_1 subunit of molecular weight approximately 48 kDa to F_2 subunit of molecular weight approximately 23 kDa is between 1:1 to about 2:1 as determined by scanning densitometry.

13. (Original) The immunogenic composition of claim 12 wherein said mixture is at least about 75% pure.

14. (Currently amended) The immunogenic composition of ~~claim 1~~ claim 3 wherein said RSV proteins in said mixture are from one or both of subtypes RSV A and RSV B.

15. to 19. (Cancelled)

20. (Currently amended) A method of immunizing a human host against disease caused by infection by respiratory syncytial virus (RSV) and by influenza virus, which comprises administering to the host an immunoeffective amount of the immunogenic composition of ~~claim 1~~ claim 3.

21. (Original) The method of claim 20 wherein said host is a human host of at least 18 years of age.